Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has received an average recommendation of “Hold” from the ten research firms that are presently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $18.40.

AMPH has been the topic of several research reports. TheStreet upgraded shares of Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Monday, June 26th. Wells Fargo & Company restated a “buy” rating on shares of Amphastar Pharmaceuticals in a research report on Saturday, July 22nd. BidaskClub cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, July 28th. Piper Jaffray Companies set a $20.00 price target on shares of Amphastar Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, July 29th. Finally, BMO Capital Markets restated a “hold” rating and issued a $16.00 price target on shares of Amphastar Pharmaceuticals in a research report on Monday, July 31st.

In other Amphastar Pharmaceuticals news, EVP Diane G. Gerst sold 8,444 shares of Amphastar Pharmaceuticals stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $18.87, for a total transaction of $159,338.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Richard K. Prins sold 5,000 shares of Amphastar Pharmaceuticals stock in a transaction on Monday, August 14th. The stock was sold at an average price of $14.80, for a total transaction of $74,000.00. Following the transaction, the director now directly owns 33,844 shares of the company’s stock, valued at $500,891.20. The disclosure for this sale can be found here. Insiders have sold 126,380 shares of company stock valued at $2,268,933 over the last ninety days. 11.10% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Sei Investments Co. boosted its stake in Amphastar Pharmaceuticals by 20,071.0% during the first quarter. Sei Investments Co. now owns 103,074 shares of the company’s stock worth $1,495,000 after buying an additional 102,563 shares during the period. Swiss National Bank boosted its stake in Amphastar Pharmaceuticals by 5.3% during the first quarter. Swiss National Bank now owns 59,400 shares of the company’s stock worth $861,000 after buying an additional 3,000 shares during the period. Comerica Bank boosted its stake in Amphastar Pharmaceuticals by 4.1% during the first quarter. Comerica Bank now owns 39,612 shares of the company’s stock worth $600,000 after buying an additional 1,570 shares during the period. OppenheimerFunds Inc. purchased a new position in Amphastar Pharmaceuticals during the first quarter worth $215,000. Finally, Tudor Investment Corp ET AL boosted its stake in Amphastar Pharmaceuticals by 33.9% during the first quarter. Tudor Investment Corp ET AL now owns 35,387 shares of the company’s stock worth $513,000 after buying an additional 8,960 shares during the period. 44.26% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/10/11/amphastar-pharmaceuticals-inc-amph-given-average-rating-of-hold-by-analysts.html.

Amphastar Pharmaceuticals (NASDAQ:AMPH) traded up 0.86% during trading on Wednesday, reaching $18.86. 148,946 shares of the company’s stock were exchanged. The stock’s 50-day moving average is $16.58 and its 200-day moving average is $16.23. The company has a market cap of $871.24 million, a P/E ratio of 244.94 and a beta of 1.69. Amphastar Pharmaceuticals has a 12-month low of $12.05 and a 12-month high of $21.75.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Wednesday, August 9th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.05. Amphastar Pharmaceuticals had a net margin of 1.61% and a return on equity of 2.42%. The company had revenue of $65.20 million for the quarter, compared to analysts’ expectations of $63.40 million. During the same quarter in the previous year, the business posted $0.23 earnings per share. Amphastar Pharmaceuticals’s quarterly revenue was down 4.1% on a year-over-year basis. Analysts predict that Amphastar Pharmaceuticals will post $0.27 EPS for the current fiscal year.

Amphastar Pharmaceuticals declared that its board has approved a stock repurchase program on Wednesday, August 9th that permits the company to buyback $20.00 million in shares. This buyback authorization permits the company to repurchase up to 2.8% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Analyst Recommendations for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.